- Home
- RVMD vs IR Comparison
RVMD vs IR Comparison
Compare RVMD & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | IR |
|---|---|---|
| Founded | 2014 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 32.6B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RVMD | IR |
|---|---|---|
| Price | $208.19 | $80.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | ★ $140.84 | $96.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.9M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.15 |
| Revenue | N/A | ★ $2,375,400,000.00 |
| Revenue This Year | N/A | $7.10 |
| Revenue Next Year | $533.02 | $4.78 |
| P/E Ratio | ★ N/A | $69.03 |
| Revenue Growth | N/A | ★ 22.48 |
| 52 Week Low | $35.62 | $68.07 |
| 52 Week High | $220.34 | $100.96 |
Technical Indicators
Market Signals| Indicator | RVMD | IR |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 42.86 |
| Support Level | $177.04 | $79.32 |
| Resistance Level | N/A | $80.87 |
| Average True Range (ATR) | 7.36 | 2.10 |
| MACD | 0.46 | -0.99 |
| Stochastic Oscillator | 71.41 | 11.90 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.